Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




ML-Powered Gas Sensors to Detect Pathogens and AMR at POC

By LabMedica International staff writers
Posted on 24 Jul 2025

Fast and accurate diagnosis is critical to improving patient care and combating the global threat of antimicrobial resistance (AMR). More...

Traditional diagnostic methods for infections, such as gas chromatography-mass spectrometry and proton transfer reaction–mass spectrometry, while effective, are expensive, technically demanding, and unsuitable for point-of-care settings. Interpreting volatile organic compounds (VOCs)—the unique chemical signatures emitted by microbes and infected tissues—can be challenging due to their complexity and overlap. Moreover, these VOC signals are often influenced by environmental variables, which adds to diagnostic inaccuracy. A report published in Cell Biomaterials explores the use of sensor systems combined with advanced computational models to detect and classify microbial VOCs with high precision.

This report by researchers at ETH Zurich (Zurich, Switzerland) presents a promising approach that combines gas sensors and machine learning for real-time infection diagnosis. The report explores how gas sensors made from nanostructured metal oxides, conductive polymers, and hybrid composites could offer a compact, affordable, and practical solution for detecting VOCs. These sensors measure changes in electrical resistance or conductance when exposed to microbial byproducts. To decode the complex patterns produced by VOCs, the researchers assessed the viability of integrating machine learning algorithms such as support vector machines (SVM), random forests, long short-term memory (LSTM) neural networks, and gradient boosting to classify sensor data and improve diagnostic accuracy. The models were assessed across bacterial cultures, infected tissues, and clinical biofluids such as urine and blood, demonstrating its ability to distinguish bacterial species and differentiate between drug-resistant and susceptible strains.

The team compiled findings from recent studies that tested these sensor-ML systems on bacterial cultures, infected tissue samples, and clinical biofluids such as urine and blood. The systems achieved high sensitivity and specificity, accurately identifying pathogens like Escherichia coli and Staphylococcus aureus, as well as detecting resistance profiles such as those involving extended-spectrum beta-lactamases. The researchers have emphasized the need for training these machine learning models on comprehensive datasets that reflect clinical variability to ensure robust performance. Ongoing efforts include miniaturizing devices for point-of-care use, functionalizing sensor surfaces, and mitigating environmental interference such as humidity and temperature. Although further development and clinical validation are necessary, these systems offer a clear path toward noninvasive, rapid diagnostics that can complement laboratory methods and support better antimicrobial stewardship.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus test in Abbott’s screening portfolio, which now spans both stool‑ and blood‑based options (Photo courtesy of Freenome)

Blood-Based Test Broadens Colorectal Cancer Screening Options

Colorectal cancer is the second-leading cause of cancer-related death in the U.S., yet outcomes improve markedly when the disease is detected through routine screening. Despite this, up to 60 million Americans... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.